CA3232633A1 - Milvexian for prevention and treatment of thromboembolic disorders - Google Patents

Milvexian for prevention and treatment of thromboembolic disorders Download PDF

Info

Publication number
CA3232633A1
CA3232633A1 CA3232633A CA3232633A CA3232633A1 CA 3232633 A1 CA3232633 A1 CA 3232633A1 CA 3232633 A CA3232633 A CA 3232633A CA 3232633 A CA3232633 A CA 3232633A CA 3232633 A1 CA3232633 A1 CA 3232633A1
Authority
CA
Canada
Prior art keywords
milvexian
daily dose
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3232633A
Other languages
English (en)
French (fr)
Inventor
John Strony
Gary Peters
Madhu Chintala
Christopher Nessel
Liyanage Vidya PERERA
Danshi LI
Joseph M. LUETTGEN
Dietmar Alfred Seiffert
Charlotte JONES-BURTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Original Assignee
Janssen Pharmaceutica NV
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Bristol Myers Squibb Co filed Critical Janssen Pharmaceutica NV
Publication of CA3232633A1 publication Critical patent/CA3232633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3232633A 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders Pending CA3232633A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US63/245,522 2021-09-17
US202163278582P 2021-11-12 2021-11-12
US63/278,582 2021-11-12
PCT/US2022/043797 WO2023043999A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Publications (1)

Publication Number Publication Date
CA3232633A1 true CA3232633A1 (en) 2023-03-23

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3232633A Pending CA3232633A1 (en) 2021-09-17 2022-09-16 Milvexian for prevention and treatment of thromboembolic disorders

Country Status (11)

Country Link
US (1) US20250099466A1 (https=)
EP (1) EP4401736A1 (https=)
JP (1) JP2024534427A (https=)
KR (1) KR20240060820A (https=)
AU (1) AU2022345862A1 (https=)
CA (1) CA3232633A1 (https=)
CL (1) CL2024000776A1 (https=)
IL (1) IL310894A (https=)
MX (1) MX2024002857A (https=)
TW (1) TW202327607A (https=)
WO (1) WO2023043999A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) * 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
TW202506125A (zh) * 2023-04-19 2025-02-16 美商必治妥美雅史谷比公司 米爾維仙(milvexian)於治療及預防患有心血管或腦血管疾病之患者之血栓病況的用途
WO2024220803A1 (en) * 2023-04-19 2024-10-24 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation
EP4698172A1 (en) * 2023-04-19 2026-02-25 Bristol-Myers Squibb Company Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112021020257A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Also Published As

Publication number Publication date
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
IL310894A (en) 2024-04-01
JP2024534427A (ja) 2024-09-20
KR20240060820A (ko) 2024-05-08
EP4401736A1 (en) 2024-07-24
US20250099466A1 (en) 2025-03-27
WO2023043999A1 (en) 2023-03-23
TW202327607A (zh) 2023-07-16
MX2024002857A (es) 2024-03-21

Similar Documents

Publication Publication Date Title
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
JP5792059B2 (ja) 抗血小板療法中の血小板抑制のメンテナンス
EP2374456B1 (en) Edoxaban dosage regime
US20040110747A1 (en) Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
TW201031651A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
US20220105065A1 (en) METHOD OF TREATING PATIENTS WITH A FACTOR Xa INHIBITOR, ASPIRIN, AND VERAPAMIL
AU2025271046A1 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
AU2017258808A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
MX2011004534A (es) Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional.
CN102600146B (zh) 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
US20050197332A1 (en) Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
Martin et al. Single-dose extended-release epidural morphine for pain after hip arthroplasty
CN118302166A (zh) 用于预防及治疗血管栓塞病症的米尔维仙
CA2993858C (en) Combination of rivaroxaban and acetylsalicylic acid for reducing the risk of cardiovascular events
Sudlow et al. Randomized trials of antiplatelet therapy
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
TW202506124A (zh) 米爾維仙(milvexian)於治療或預防患有急性冠狀動脈症候群之患者之不良腦血管事件或不良心血管事件的用途
KR20170005088A (ko) Adhd의 치료를 위한 방법 및 다소트랄린의 투약량
MXPA04001174A (es) Tratamiento para lipodistrofia.
HK1161984B (en) Edoxaban dosage regime
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240731

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240731

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250729